TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
– Proven to deliver significant and robust triglyceride reductions –
– Only treatment for sHTG indicated to reduce the risk of acute pancreatitis –
– Ionis’ first independent commercial launch in a prevalent condition –
– Ionis to host webcast today at 3:30 p.m. ET –
FDA approves Tryngolza to reduce triglycerides, pancreatitis risk in hypertriglyceridemia
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
Ionis wins FDA label expansion for potential blockbuster triglycerides indication
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk - Ionis Pharmaceuticals
Ionis scores transformational FDA label expansion for Tryngolza
Elecoglipron, an oral daily GLP-1, confers glucose, weight reduction in phase 2 studies
The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk…
Olezarsen indicated as an adjunct to diet
In patients with severe hypertriglyceridemia, olezarsen lowered triglycerides and reduced acute pancreatitis events compared with…
Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with…
Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing deal for zilganersen
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the first…
